Member Info for jackdaw99

... and up-day after yesterday's buying?

Agreed. Great result. Remember that appeals are granted only when there are substantial grounds for overturn or new evidence becomes relevant. Costs don't seem that gloomy and the apparent willingness to cooperate with Illumina (to repeated rebuffs??) surely counts in our favour. I only hope that the Thermo cash means that better witnesses are drafted in on the NIPT side - it's hard to say without being there, but the written account didn't make our helpers sound that helpful.

... that, even with today's volume, only 2% traded. Should see holdings RNS soon though, one would think?

https://www.theguardian.com/society/2018/jan/23/number-of-new-antibiotics-has-fallen-sharply-since-2000

Sub or Evens cash, yes. Spending substantial, prospects potentially much greater!

Looks like the institutions know where this is heading? Consolidation - NASDAQ - Re-Rate???

I'm not so quick to judge. Having been in management jobs myself (up to 300 staff) I know that you can be achieving a great deal, by working yourself to the bone, but it's not always visible to those outside the gates, nor can it be if you want to be successful and not give away everything to rivals. But it's what happens long-term that matters, so if NASDAQ happens and we access lots of funding and the price goes to a pound, I won't care about how we got there!

Can't blame them - some will have doubled, tripled and quadrupled. Everyone has different priorities.

... time to buy again??

That's due to MMs putting their underpants over their trousers in the morning after too many champers the night before.

Freddie, It's part of the OXB salary arrangement and he gets it every month in lieu of pay, "Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price." Still good of him though.....

They will probably have more indications in cancer to pursue with Novartis, they have their own pipeline (possible cancer & Parkinson's) that have been very quiet lately, and there may, according to some, be a Novartis TO at some point. The 13 pence doesn't take all of these into account.

It was a Top Share Tip for 2018 (published Dec 31 2017) as follows: Iain Dey Oxford BioMedica Backing British biotech has served me well this year, so I am going to attempt to repeat the trick. Medicine is making quicker advances than the general public seems to acknowledge. One biotech that seems to offer upside, with limited downside, is Oxford BioMedica. 'Having more than doubled this year to 8.85p on the back of test results that showed one of its treatments could help cure a form of childhood leukaemia, it is not necessarily an obvious choice for 2018. Nonetheless, Peel Hunt and Jefferies both have a price target of 13p per share, implying more than 40% upside......." etc etc

... looking nice.

Smoke & Mirrors...

... bet my cotton socks they are buys. This share has IMO one of the least reliable buy-sell indicators in the market!

..and steady buying, which I doubt is still retail buying from the Sunday Times effect. Serious accumulation that I guess might be Novartis. Makes sense to me anyway.

Appears that Therno are keen to support, so good news IMO.

Excellent news on expansion of applications.

Great summary - thanks!